5JZ7

NGF IN COMPLEX WITH MEDI578 scFv


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free: 0.268 
  • R-Value Work: 0.258 
  • R-Value Observed: 0.258 

wwPDB Validation   3D Report Full Report


This is version 1.0 of the entry. See complete history


Literature

Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.

Dobson, C.L.Devine, P.W.Phillips, J.J.Higazi, D.R.Lloyd, C.Popovic, B.Arnold, J.Buchanan, A.Lewis, A.Goodman, J.van der Walle, C.F.Thornton, P.Vinall, L.Lowne, D.Aagaard, A.Olsson, L.L.Ridderstad Wollberg, A.Welsh, F.Karamanos, T.K.Pashley, C.L.Iadanza, M.G.Ranson, N.A.Ashcroft, A.E.Kippen, A.D.Vaughan, T.J.Radford, S.E.Lowe, D.C.

(2016) Sci Rep 6: 38644-38644

  • DOI: 10.1038/srep38644
  • Primary Citation of Related Structures:  
    5JZ7

  • PubMed Abstract: 
  • Uncontrolled self-association is a major challenge in the exploitation of proteins as therapeutics. Here we describe the development of a structural proteomics approach to identify the amino acids responsible for aberrant self-association of monoclonal antibodies and the design of a variant with reduced aggregation and increased serum persistence in vivo ...

    Uncontrolled self-association is a major challenge in the exploitation of proteins as therapeutics. Here we describe the development of a structural proteomics approach to identify the amino acids responsible for aberrant self-association of monoclonal antibodies and the design of a variant with reduced aggregation and increased serum persistence in vivo. We show that the human monoclonal antibody, MEDI1912, selected against nerve growth factor binds with picomolar affinity, but undergoes reversible self-association and has a poor pharmacokinetic profile in both rat and cynomolgus monkeys. Using hydrogen/deuterium exchange and cross-linking-mass spectrometry we map the residues responsible for self-association of MEDI1912 and show that disruption of the self-interaction interface by three mutations enhances its biophysical properties and serum persistence, whilst maintaining high affinity and potency. Immunohistochemistry suggests that this is achieved via reduction of non-specific tissue binding. The strategy developed represents a powerful and generic approach to improve the properties of therapeutic proteins.


    Organizational Affiliation

    MedImmune Ltd, Granta Park, Cambridge, CB21 6GH, UK.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Beta-nerve growth factorA, B, E, F110Homo sapiensMutation(s): 0 
Gene Names: NGFNGFB
UniProt & NIH Common Fund Data Resources
Find proteins for P01138 (Homo sapiens)
Explore P01138 
Go to UniProtKB:  P01138
PHAROS:  P01138
GTEx:  ENSG00000134259 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP01138
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
MEDI578 scFv, heavy chainC, G, H, J130Homo sapiensMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetailsImage
MEDI578 scFv, light chainD, I, K, L122Homo sapiensMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free: 0.268 
  • R-Value Work: 0.258 
  • R-Value Observed: 0.258 
  • Space Group: I 4
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 182.085α = 90
b = 182.085β = 90
c = 109.832γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
MOSFLMdata reduction
SCALAdata scaling
PHASERphasing

Structure Validation

View Full Validation Report




Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2017-01-11
    Type: Initial release